Nautilus Biotechnology reported Q1 2026 net loss of $14.7 million, improved from $16.6 million prior year, with operating expenses down 14% to $16.1 million and cash position of $143.4 million.
Key takeaways
Operating expenses decreased 14% to $16.1 million from $18.8 million year-ago quarter due to lower salaries, benefits, stock compensation, and facilities costs.
Net loss improved to $14.7 million from $16.6 million in Q1 2025.
Cash, cash equivalents, and investments stood at $143.4 million as of March 31, 2026.
Initiated Iterative Mapping Early Access Program with Baylor College of Medicine as first customer for Tau proteoform assay.
Appointed Amber Faust as VP of Global Sales to drive Early Access expansion and Voyager Platform adoption.